Advertisement Synairgen to receive Japanese patent for inhaled IFN-beta - Pharmaceutical Business review
Pharmaceutical Business review is using cookies

ContinueLearn More

Synairgen to receive Japanese patent for inhaled IFN-beta

Synairgen, a UK based respiratory drug discovery and development company, is set to receive Japanese patent for its inhaled interferon beta (IFN-beta) as a treatment for rhinovirus infections in asthma and COPD patients.

The patent is a part of patent portfolio owned by the University of Southampton, which is exclusively licensed to Synairgen.

Using in vitro human models, it was discovered that local delivery of IFN-beta to the lungs could limit the spread of virus to lungs in subjects with respiratory disease and the consequent worsening of their symptoms.

Synairgen has entered into a supply and license agreement for a patent-protected formulation of IFN-beta from the Rentschler Group in Germany.

Synairgen CEO Richard Marsden said the Japanese patent protects a significant market and complements their US and European patents.